2019 - Meridian Medical Technologies | Mylan Pharmaceuticals Inc. | Novitium Pharma LLC


Drug Enforcement Administration

Importer of Controlled Substances Registration

[DRG No. 20-017]

ACTION: Notice of registration.

SUMMARY: The registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as importers of schedule II controlled substances.

SUPPLEMENTARY INFORMATION: The companies listed below applied to be registered as an importers of various basic classes of schedule II controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for a hearing were submitted for these notices.

Company FR Docket Published
Meridian Medical Technologies 84 FR 68473 December 16, 2019
Mylan Pharmaceuticals Inc. 84 FR 68474 December 16, 2019
Novitium Pharma LLC 84 FR 68474 December 16, 2019

The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrants to import the applicable various basic classes of schedule II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each of the company's maintenance of effective controls against diversion by inspecting and testing each company's physical security systems, verifying each company's compliance with state and local laws, and reviewing each company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule II controlled substances to the above listed companies.

Dated: 2/10/2020

William T. McDermott,
Assistant Administrator.